About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | REBYOTA™ Prospective Registry

REBYOTA™ Prospective Registry

NCT05835219·42 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Ferring Pharmaceuticals

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Signed and dated informed consent form (ICF)
Age ≥ 18 years
Diagnosis of rCDI as determined by the treating physician
Completed antibiotic treatment for the presenting rCDI episode
Prescription for REBYOTA™ to prevent rCDI according to the approved indication

You may not be if

Currently enrolled in an interventional clinical trial

The record

StatusCompleted

PhaseNo phase

Taking part145

StartedJun 2023

UpdatedJan 28, 2026

Conditions

Recurrence of Clostridium Difficile Infection

Where42

Ferring Investigational Site
Chandler, Arizona, United States
Ferring Investigational Site
Chula Vista, California, United States
Ferring Investigational Site
Murrieta, California, United States